Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 3,200 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 3,200 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $39.91, for a total transaction of $127,712.00. Following the transaction, the insider directly owned 84,515 shares in the company, valued at $3,372,993.65. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Castle Biosciences Stock Performance

CSTL stock traded down $0.39 during mid-day trading on Friday, reaching $32.02. The company had a trading volume of 36,281 shares, compared to its average volume of 389,691. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02. The stock’s 50-day simple moving average is $39.51 and its two-hundred day simple moving average is $29.52. The stock has a market capitalization of $934.49 million, a P/E ratio of -70.78 and a beta of 1.06. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The firm had revenue of $80.55 million for the quarter, compared to analysts’ expectations of $71.06 million. Research analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC raised its stake in Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after buying an additional 1,391 shares during the period. State of Alaska Department of Revenue bought a new position in Castle Biosciences during the 3rd quarter worth $35,000. CWM LLC lifted its position in Castle Biosciences by 80.6% during the third quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after purchasing an additional 853 shares during the period. Jones Financial Companies Lllp lifted its stake in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on CSTL shares. Lake Street Capital lifted their price objective on Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, January 12th. BTIG Research boosted their price objective on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Robert W. Baird increased their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday, November 4th. KeyCorp reissued an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a report on Thursday, January 29th. Finally, Guggenheim upped their price target on Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, January 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $47.14.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.